[go: up one dir, main page]

WO2010072398A3 - Pharmaceutical formulations comprising buprenorphine and an alcohol - Google Patents

Pharmaceutical formulations comprising buprenorphine and an alcohol Download PDF

Info

Publication number
WO2010072398A3
WO2010072398A3 PCT/EP2009/009196 EP2009009196W WO2010072398A3 WO 2010072398 A3 WO2010072398 A3 WO 2010072398A3 EP 2009009196 W EP2009009196 W EP 2009009196W WO 2010072398 A3 WO2010072398 A3 WO 2010072398A3
Authority
WO
WIPO (PCT)
Prior art keywords
alcohol
buprenorphine
pharmaceutical formulations
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/009196
Other languages
French (fr)
Other versions
WO2010072398A2 (en
Inventor
Philip Watson
Claire Fowler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Ltd
Original Assignee
Boehringer Ingelheim Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Ltd filed Critical Boehringer Ingelheim Ltd
Publication of WO2010072398A2 publication Critical patent/WO2010072398A2/en
Publication of WO2010072398A3 publication Critical patent/WO2010072398A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof and an alcohol, said formulation containing ≤1% w/v of buprenorphine or said salt thereof and a pharmaceutical formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof and an alcohol, said formulation containing ≤3% w/v of alcohol and their uses as analgesics or sedatives. The invention also relates to a product comprising a vessel with a re-sealable closure containing 5 to 50 ml, preferably 10 to 20 ml, of a pharmaceutical formulation comprising buprenorphine or a pharmaceutically acceptable salt thereof and an alcohol, preferably benzyl alcohol.
PCT/EP2009/009196 2008-12-22 2009-12-21 Veterinary formulations Ceased WO2010072398A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08254107 2008-12-22
EP08254107.9 2008-12-22

Publications (2)

Publication Number Publication Date
WO2010072398A2 WO2010072398A2 (en) 2010-07-01
WO2010072398A3 true WO2010072398A3 (en) 2010-11-25

Family

ID=40655918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/009196 Ceased WO2010072398A2 (en) 2008-12-22 2009-12-21 Veterinary formulations

Country Status (1)

Country Link
WO (1) WO2010072398A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0069600A2 (en) * 1981-07-10 1983-01-12 Reckitt And Colman Products Limited Pharmaceutical compositions
WO2003080022A2 (en) * 2002-03-19 2003-10-02 Ionix Pharmaceuticals Limited Analgesics for nasal administration
US20070117828A1 (en) * 2005-11-21 2007-05-24 Schering-Plough Animal Health Corp. Pharmaceutical compositions
WO2008047163A1 (en) * 2006-10-18 2008-04-24 Pharmasol Limited Buprenorphine-containing non-pressurised spray composition for transmucosal administration
WO2008106571A2 (en) * 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0069600A2 (en) * 1981-07-10 1983-01-12 Reckitt And Colman Products Limited Pharmaceutical compositions
WO2003080022A2 (en) * 2002-03-19 2003-10-02 Ionix Pharmaceuticals Limited Analgesics for nasal administration
US20070117828A1 (en) * 2005-11-21 2007-05-24 Schering-Plough Animal Health Corp. Pharmaceutical compositions
WO2008047163A1 (en) * 2006-10-18 2008-04-24 Pharmasol Limited Buprenorphine-containing non-pressurised spray composition for transmucosal administration
WO2008106571A2 (en) * 2007-02-28 2008-09-04 Abbott Laboratories Sustained release parenteral formulations of buprenorphine

Also Published As

Publication number Publication date
WO2010072398A2 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2007146248A3 (en) Stable laquinimod preparations
WO2012021715A3 (en) Stable formulations of linaclotide
WO2009103884A3 (en) Composition for human and/or animal nutrition, uses thereof and yeasts
WO2010021607A3 (en) Pharmaceutical formulation
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
IL196891A (en) (3-amino-1,2,3,4-tetrahydro-9h-carbazol--9-yl)-acetic acid derivatives, pharmaceutical compositions containing them and their use in the preparation of medicaments
WO2012064126A3 (en) Medical adhesive composition
IL192670A (en) 1,3-dioxane carboxylic acids, process for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2010016686A3 (en) Nanoemulsion for local administration
WO2010072958A3 (en) Topical pharmaceutical composition containing a water-sensitive active principle
WO2009141541A3 (en) Use of kif13a and ap-1 inhibitors for inhibiting melanogenesis
WO2011141488A3 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012130820A3 (en) Isopentyl esters for the use in cosmetic, dermatological, or pharmaceutical compositions
WO2008113901A3 (en) Composition with controlled release of levetiracetam and method for preparing same
WO2009060952A1 (en) Novel preparation
WO2010041832A3 (en) Antioxidant active composition containing an ishige okamurae-derived compound
WO2012161497A3 (en) Peptide derivatives having a superior moisturizing effect and uses thereof
WO2008107092A3 (en) Use of derivatives of 4-hydroxyphenoxy acetic acid
IL178425A0 (en) Carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
MX2009003060A (en) Emulsion.
EP2196463A4 (en) Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof
WO2008092219A3 (en) Pharmaceutical composition comprising tramadol and ketoprofen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09795724

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09795724

Country of ref document: EP

Kind code of ref document: A2